NEW YORK (GenomeWeb) — The Mayo Clinic and biomedical investing firm Invenshure have launched a new company, Oneome, to provide analysis of NGS data and reporting of relevant pharmacogenomic information in an accessible format.
Terms of the investment were not disclosed, but John Logan Black, co-founder of the new company and co-director of the Mayo Clinic's Personalize Genomics Lab, told GenomeWeb Daily News that the company is 50 percent owned by Mayo and 50 percent owned by Invenshure.
Oneome will initially provide analysis of patient NGS data generated within the Mayo Clinic, providing concise, actionable reports to help physicians deliver the right medication and avoid serious side effects. The company then intends to launch its service more broadly to other customers seeking PGx-focused analysis and reporting of NGS results.
The Mayo Clinic Department of Laboratory Medicine and Pathology and the Mayo Clinic Center for Individualized Medicine are responsible for the research and development of the algorithms behind Oneome's analysis methodology.
In addition to the investment, Invenshure will contribute its data processing platform, which will be combined with Mayo's pharmacogenomics knowledge base. "Together, we expect the unique combination of our respective technologies to rapidly enable health care IT solutions that will save lives and reduce costs," Invenshure Co-founder and Oneome CEO Troy Kopischke said in a statement.
Oneome's reports will focus on the most established and actionable PGx variants — alterations which professional guidelines endorse to inform the prescribing of a medication, or which are included in warning labels for specific drugs.